Cordycepin is improved to decrease the drug resistance of NSCLC by inhibiting the AMPK signaling pathway and inhibit NSCLC with cisplatin resistance by the AMPK signaling pathway and AKT signaling pathway (Wei et al., 2019) (Liao et al., 2020). This evidence concerns the gene AKT1 and non-small cell lung carcinoma.